Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 169

1.

Bystander Effect Induced by Electroporation is Possibly Mediated by Microvesicles and Dependent on Pulse Amplitude, Repetition Frequency and Cell Type.

Prevc A, Bedina Zavec A, Cemazar M, Kloboves-Prevodnik V, Stimac M, Todorovic V, Strojan P, Sersa G.

J Membr Biol. 2016 Jul 1. [Epub ahead of print]

PMID:
27371159
2.

European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer.

Bertino G, Sersa G, De Terlizzi F, Occhini A, Plaschke CC, Groselj A, Langdon C, Grau JJ, McCaul JA, Heuveling D, Cemazar M, Strojan P, de Bree R, Leemans CR, Wessel I, Gehl J, Benazzo M.

Eur J Cancer. 2016 Aug;63:41-52. doi: 10.1016/j.ejca.2016.05.001. Epub 2016 Jun 4.

PMID:
27267144
3.

Tumor radiosensitization by gene therapy against endoglin.

Stimac M, Kamensek U, Cemazar M, Kranjc S, Coer A, Sersa G.

Cancer Gene Ther. 2016 Jul;23(7):214-20. doi: 10.1038/cgt.2016.20. Epub 2016 May 20.

PMID:
27199221
4.

Cytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluation.

Grabner S, Modec B, Bukovec N, Bukovec P, Čemažar M, Kranjc S, Serša G, Sčančar J.

J Inorg Biochem. 2016 Aug;161:40-51. doi: 10.1016/j.jinorgbio.2016.04.031. Epub 2016 Apr 26.

PMID:
27189143
5.

Electrochemotherapy by pulsed electromagnetic field treatment (PEMF) in mouse melanoma B16F10 in vivo.

Kranjc S, Kranjc M, Scancar J, Jelenc J, Sersa G, Miklavcic D.

Radiol Oncol. 2016 Feb 16;50(1):39-48. doi: 10.1515/raon-2016-0014. eCollection 2016 Mar 1.

PMID:
27069448
6.

Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients.

Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M.

Radiol Oncol. 2016 Feb 16;50(1):21-7. doi: 10.1515/raon-2015-0048. eCollection 2016 Mar 1.

PMID:
27069446
7.

Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review.

Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G.

Radiol Oncol. 2016 Feb 16;50(1):1-13. doi: 10.1515/raon-2016-0006. eCollection 2016 Mar 1. Review.

PMID:
27069444
8.

Magnetic field contributes to the cellular uptake for effective therapy with magnetofection using plasmid DNA encoding against Mcam in B16F10 melanoma in vivo.

Prosen L, Hudoklin S, Cemazar M, Stimac M, Lampreht Tratar U, Ota M, Scancar J, Romih R, Sersa G.

Nanomedicine (Lond). 2016 Mar;11(6):627-41. doi: 10.2217/nnm.16.4. Epub 2016 Mar 8.

PMID:
27021639
9.

Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy.

Groselj A, Krzan M, Kosjek T, Bosnjak M, Sersa G, Cemazar M.

Cancer Chemother Pharmacol. 2016 May;77(5):939-47. doi: 10.1007/s00280-016-3004-z. Epub 2016 Mar 18.

PMID:
26992379
10.

Radioactivity of cigarettes and the importance of (210)Po and thorium isotopes for radiation dose assessment due to smoking.

Kubalek D, Serša G, Štrok M, Benedik L, Jeran Z.

J Environ Radioact. 2016 May;155-156:97-104. doi: 10.1016/j.jenvrad.2016.02.015. Epub 2016 Mar 1.

PMID:
26942842
11.

Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours.

Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, Tesic N, Lampreht Tratar U, Rak M, Tozon N.

Vet Comp Oncol. 2016 Feb 3. doi: 10.1111/vco.12208. [Epub ahead of print]

PMID:
26840222
12.

Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects.

Dolinsek T, Sersa G, Prosen L, Bosnjak M, Stimac M, Razborsek U, Cemazar M.

Cancers (Basel). 2015 Dec 24;8(1). pii: E3. doi: 10.3390/cancers8010003.

PMID:
26712792
13.

Clinical potential of electroporation for gene therapy and DNA vaccine delivery.

Lambricht L, Lopes A, Kos S, Sersa G, Préat V, Vandermeulen G.

Expert Opin Drug Deliv. 2016 Feb;13(2):295-310. doi: 10.1517/17425247.2016.1121990. Epub 2015 Dec 19.

PMID:
26578324
14.

Variation in dielectric properties due to pathological changes in human liver.

Peyman A, Kos B, Djokić M, Trotovšek B, Limbaeck-Stokin C, Serša G, Miklavčič D.

Bioelectromagnetics. 2015 Dec;36(8):603-12. doi: 10.1002/bem.21939. Epub 2015 Oct 28.

PMID:
26508012
15.

Electrochemotherapy of colorectal liver metastases--an observational study of its effects on the electrocardiogram.

Mali B, Gorjup V, Edhemovic I, Brecelj E, Cemazar M, Sersa G, Strazisar B, Miklavcic D, Jarm T.

Biomed Eng Online. 2015;14 Suppl 3:S5. doi: 10.1186/1475-925X-14-S3-S5. Epub 2015 Aug 27.

PMID:
26356120
16.

Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy.

Groselj A, Kos B, Cemazar M, Urbancic J, Kragelj G, Bosnjak M, Veberic B, Strojan P, Miklavcic D, Sersa G.

Biomed Eng Online. 2015;14 Suppl 3:S2. doi: 10.1186/1475-925X-14-S3-S2. Epub 2015 Aug 27.

PMID:
26355773
17.

Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer.

Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, Miklavcic D.

Cancer Immunol Immunother. 2015 Oct;64(10):1315-27. doi: 10.1007/s00262-015-1724-2. Epub 2015 Jun 12. Review.

PMID:
26067277
18.

Endoglin (CD105) Silencing Mediated by shRNA Under the Control of Endothelin-1 Promoter for Targeted Gene Therapy of Melanoma.

Tesic N, Kamensek U, Sersa G, Kranjc S, Stimac M, Lampreht U, Preat V, Vandermeulen G, Butinar M, Turk B, Cemazar M.

Mol Ther Nucleic Acids. 2015 May 5;4:e239. doi: 10.1038/mtna.2015.12.

PMID:
25942402
19.

Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.

Stimac M, Dolinsek T, Lampreht U, Cemazar M, Sersa G.

PLoS One. 2015 Apr 24;10(4):e0124913. doi: 10.1371/journal.pone.0124913. eCollection 2015.

PMID:
25909447
20.

Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.

Mirković B, Markelc B, Butinar M, Mitrović A, Sosič I, Gobec S, Vasiljeva O, Turk B, Čemažar M, Serša G, Kos J.

Oncotarget. 2015 Aug 7;6(22):19027-42.

PMID:
25848918
Items per page

Supplemental Content

Write to the Help Desk